Compare Global X Autonomous & Electric Vehicles (DRIV) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Autonomous & Electric Vehicles vs Viatris Inc — how do they compare? Global X Autonomous & Electric Vehicles trades at $32.8 (market cap $356.37M), while Viatris Inc trades at $17.49 (market cap $20.03B). The key difference: Viatris Inc is far larger — about 56.2× Global X Autonomous & Electric Vehicles's market cap, and Viatris Inc pays a 2.75% dividend while Global X Autonomous & Electric Vehicles pays none. Which is the better fit depends on your goals — on Pluang, investors hold Global X Autonomous & Electric Vehicles for 40 Days and Viatris Inc for 57 Days on average.
| DRIV | VTRS | |
|---|---|---|
Market Cap | $356.37M | $20.03B |
Volume | 22,397 | 14,109,977 |
Sector | Sector/Thematic | Health |
52-Week High | $42.53 | $18.27 |
52-Week Low | $27.58 | $9.74 |
Typical Hold Time | 40 Days | 57 Days |
Enterprise Value | — | $32.15B |
Dividend Yield | — | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DRIV trades at $33.37, down 1.68% today amid mixed technical signals. The overall technical outlook is bullish with neutral oscillators, while key support sits at $33. Recent news highlights automotive sector focus on hybrid and electric vehicles, though company-specific financial ratios are currently unavailable for analysis.
The stock shows technical resilience near support levels with bullish momentum indicators. Investment appeal hinges on forthcoming financial disclosures and sector trends favoring EV/hybrid adoption. Key risks include sector competition and reliance on broader automotive market performance without current fundamental data.
Viatris (VTRS) trades at $17.49, down 0.29% with a bullish technical signal and strong recent earnings beats. The company shows improving operational cash flow of $2.32B in 2025 and positive revenue growth trends, though profitability remains challenged with negative net margins. Recent developments include FDA approval for WAKIX in Japan and consistent dividend payments, supporting the bullish analyst consensus with a $22.17 price target representing 27% upside potential.
The outlook remains cautiously optimistic with strong cash generation supporting shareholder returns, but investors face risks from persistent negative profitability and high debt levels. The stock offers value appeal with reasonable P/S and P/B ratios, though the elevated P/E ratio reflects current earnings challenges that need resolution for sustained re-rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global X Autonomous & Electric Vehicles
DRIV invests in companies involved in autonomous driving and electric vehicle production. It tracks the Solactive Autonomous & Electric Vehicles Index, focusing on software and hardware leaders like Tesla, NVIDIA, and Microsoft.
Read more on DRIV →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
